Atopic dermatitis treatment selection should follow patient-specific factors, not a one-size-fits-all ladder — that's the core of a new physician discussion featuring Walter Liszewski, MD, published by HCPLive.

Liszewski, a dermatologist, addresses the question clinicians face every day in the clinic: which therapy fits which patient, and when. His comments come amid a rapidly widening atopic dermatitis armamentarium, where topical agents, systemic immunomodulators and biologics now compete for the same patients.

What factors does Liszewski point to?

The interview format doesn't reduce to a single protocol. Instead, Liszewski frames treatment choice as a weighing of individual patient variables — the considerations dermatologists routinely balance when they move from first-line topical care to systemic options.

The discussion sits within a broader clinical conversation. Atopic dermatitis affects a substantial share of both children and adults, and the past several years have added multiple targeted systemic options to prescribers' menus, making the selection question more consequential, not less.

Why does selection matter now?

More agents don't automatically mean better outcomes. Each new class brings its own dosing, monitoring and patient-fit considerations, and dermatologists must match those characteristics to disease severity, patient preference and practical factors like access and adherence.

That's the gap interviews like this one aim to close: giving clinicians a concise, expert-voiced framework for sequencing and selecting therapy rather than a simple menu review.

HCPLive's physician-interview series regularly puts these practical questions to practicing dermatologists, and Liszewski's contribution adds to that coverage at a moment when atopic dermatitis treatment algorithms are being redrawn.

For clinicians, the takeaway is straightforward: selection criteria, not drug counts, will determine whether the expanded pipeline translates into better disease control for the patients in front of them.